Pathways: [complement system](/mechanisms/complement-system-pathway), [neurotrophic signaling](/mechanisms/neurotrophic-factor-signaling), [cell death pathways](/mechanisms/cell-death-pathways-neurodegeneration)
Overview
This therapeutic strategy targets gasdermin proteins — the executioners of pyroptosis, a highly inflammatory form of programmed cell death increasingly implicated in neurodegenerative disease progression. Unlike apoptosis, pyroptosis involves gasdermin D (GSDMD) and gasdermin E (GSDME/DFNA5) forming membrane pores that release inflammatory cytokines (IL-1β, IL-18) and alarmins, driving chronic [neuroinflammation](/mechanisms/neuroinflammation) and neuronal loss. In [Alzheimer's disease](/diseases/alzheimers-disease), [Parkinson's disease](/diseases/parkinsons-disease), and ALS, repeated sub-lethal pyroptotic activation creates a self-perpetuating inflammatory loop that accelerates disease progression.[@shi2017][@liu2023]
Target
Primary Target: GSDMD catalytic domain (pore-forming domain) or GSDME[@burdette2022]
Target Type: Small-molecule inhibitor, peptide inhibitor, or antibody blocking oligomerization
Expression: Expressed in [microglia](/cell-types/microglia), [astrocytes](/cell-types/astrocytes), and neurons; upregulated in disease states[@liu2023]
Localization: Cytoplasmic protein; active cleaved fragments translocate to plasma membrane
Mechanistic Rationale
Pyroptosis is a highly inflammatory cell death modality distinct from apoptosis. While cGAS-STING inhibition blocks the upstream type I interferon response, gasdermin inhibition blocks a parallel inflammatory axis driven by caspase-1/caspase-4/5 activation:[@shi2017]
NLRP3 inflammasome activation: In neurodegeneration, aggregated proteins (amyloid-beta, tau, [alpha-synuclein](/proteins/alpha-synuclein)), mitochondrial DAMPs, and damaged mitochondria activate NLRP3 → caspase-1
Gasdermin cleavage: Active caspase-1 cleaves GSDMD (and GSDME in some cell types) into N-terminal (pore-forming) and C-terminal (inhibitory) fragments
Membrane pore formation: GSDMD-NT oligomerizes at the plasma membrane, forming 10-20nm pores
Inflammatory release: IL-1β and IL-18 (pre-formed and activated by caspase-1) are released through pores; cellular swelling leads to lysis
Chronic [neuroinflammation](/mechanisms/neuroinflammation): Released alarmins (HMGB1, ATP, S100A8/A9) propagate inflammation to neighboring cells
Critically, GSDMD knockout mice show dramatically reduced [neuroinflammation](/mechanisms/neuroinflammation) in AD and PD models[@yin2023][@zhou2022], making this a high-value target with strong genetic validation.[@yin2023][@zhou2022]
Mermaid diagram (expand to render)
Cross-links to relevant mechanisms:
Pyroptosis in Neurodegeneration
NLRP3 Inflammasome
Neuroinflammation
Inflammasome Activation
Caspase-1 in Neurodegeneration
Microglia and Neuroinflammation
Astrocyte Reactivity
Rubric Score
| Dimension | Score | Rationale | |-----------|-------|-----------| | Novelty | 8/10 | Gasdermin inhibitors are actively researched in oncology but virtually unexplored for neurodegeneration; GSDMD knockout mice show dramatic [neuroprotection](/therapeutics/neuroprotection) | | Mechanistic Rationale | 9/10 | Strong genetic validation (GSDMD KO mice protected); pathway intersects with multiple neurodegenerative mechanisms (NLRP3, cGAS-STING, [mitochondrial dysfunction](/mechanisms/mitochondrial-dysfunction)) | | Addresses Root Cause | 7/10 | Blocks inflammatory cell death but not upstream aggregation; addresses "secondary damage" from proteinopathy | | Delivery Feasibility | 7/10 | Small molecules like disulfiram and dimethyl fumarate cross BBB; novel GSDMD inhibitors in development | | Safety Plausibility | 8/10 | GSDMD KO mice are viable and healthy; pyroptosis inhibition may reduce infection risk but less severe than STING inhibition | | Combinability | 9/10 | Highly orthogonal to anti-aggregation therapies; combines well with NLRP3 inhibitors, cGAS-STING blockers, and neuroprotective approaches | | Biomarker Availability | 7/10 | CSF IL-1β, IL-18, and GSDMD cleavage products can be measured; less validated than IFN signature | | De-risking Path | 8/10 | GSDMD KO mice protected in AD/PD models; disulfiram is FDA-approved for other uses; tool compounds available | | Multi-disease Potential | 9/10 | Validated in AD, PD, ALS, FTD, and aging; pyroptosis is a common endpoint across proteinopathies | | Patient Impact | 8/10 | Reducing chronic [neuroinflammation](/mechanisms/neuroinflammation) from pyroptotic cell death could significantly slow progression | | Total | 80/100 | |
De-risking Path
Phase 1 — Lead identification: Screen FDA-approved drugs (disulfiram, dimethyl fumarate) and natural products for GSDMD inhibition; develop high-throughput GSDMD cleavage assay
Phase 2 — Optimization: Medicinal chemistry to improve potency and BBB penetration; structure-activity relationship on disulfiram analogs
Phase 3 — Cellular validation: Test in iPSC-derived [microglia](/cell-types/microglia) and neurons exposed to Aβ42, tau, or α-syn; measure IL-1β release, pyroptosis markers, and cell survival
Phase 4 — Model efficacy: Test in 5xFAD mice (AD), α-syn pre-formed fibril mice (PD), and SOD1-G93A mice (ALS); measure [neuroinflammation](/mechanisms/neuroinflammation) and behavioral outcomes
Phase 5 — Safety: Chronic toxicology in rodents and non-human primates; assess infection susceptibility during extended dosing
Disease Coverage
| Disease | Relevance | Rationale | |---------|-----------|-----------| | Alzheimer's Disease | High | Aβ activates NLRP3 → GSDMD cleavage; GSDMD KO reduces inflammation and improves cognition in APP/PS1 mice[@yin2023] | | Parkinson's Disease | High | α-syn oligomers activate NLRP3; GSDMD-mediated inflammation contributes to dopaminergic neuron loss[@zhou2022] | | [ALS](/diseases/amyotrophic-lateral-sclerosis)/[FTD](/diseases/frontotemporal-dementia) | High | TDP-43 and SOD1 mutations activate inflammasome; GSDMD cleavage detected in ALS patient spinal cord | | Frontotemporal Dementia | Medium | Tau pathology activates pyroptosis pathway; limited patient data but strong mechanistic rationale | | Aging/Inflammaging | High | Age-related DAMPs accumulate and trigger chronic low-level pyroptosis | | PSP | Medium | 4R tauopathy with [neuroinflammation](/mechanisms/neuroinflammation) component; GSDMD role being characterized |
Combination Therapy Potential
With NLRP3 inhibitors (MCC950, dapansutrile): Block upstream inflammasome activation while also inhibiting downstream gasdermin pore formation — dual inhibition for maximum anti-inflammatory effect
With cGAS-STING inhibitors: Address both DNA-sensing (cGAS-STING) and protein-aggregation-sensing (NLRP3-GSDMD) inflammatory pathways simultaneously
With anti-aggregation therapies: Reduce inflammatory "fuel" from protein aggregates while blocking the inflammatory response to whatever aggregates remain
Related NeuroWiki Pages
Pyroptosis in Neurodegeneration | NLRP3 Inflammasome
Milestone: Phase 1 safety data and biomarker modulation in patients
Actionable Next Steps
Immediate (Week 1-2): Contract research organization to screen FDA-approved drug library for GSDMD inhibition using established cleavage assay[@kayagaki2015]
Short-term (Month 1-2): Establish iPSC-derived [microglia](/cell-types/microglia) and neuronal cultures from AD/PD patients for in vitro screening
Medium-term (Month 2-4): Engage with academic collaborators (e.g.,Dr. Christian Y. Lee, MIT) for access to GSDMD KO mice
Partnership (Month 4-8): Identify pharma partner with [neuroinflammation](/mechanisms/neuroinflammation) franchise for co-development; target companies with existing NLRP3 programs (e.g., Roche, Novartis)
[Liu Y, Wu J, Wang B, et al, Gasdermin D in neurodegenerative diseases (2023)](https://pubmed.ncbi.nlm.nih.gov/37620247/)
[Yin J, Li J, Wang Y, et al, Gasdermin D deficiency attenuates [neuroinflammation](/mechanisms/neuroinflammation) and improves cognitive function in [Alzheimer's disease](/diseases/alzheimers-disease) mouse model (2023)](https://pubmed.ncbi.nlm.nih.gov/36758547/)
[Zhou Y, Lu M, Du RH, et al, Targeting GSDMD-mediated pyroptosis for [neuroprotection](/therapeutics/neuroprotection) in [Parkinson's disease](/diseases/parkinsons-disease) (2022)](https://pubmed.ncbi.nlm.nih.gov/36194412/)
[Burdette D, Vasquez J, Zeng Y, et al, Dimethyl fumarate inhibits gasdermin-mediated pyroptosis (2022)](https://pubmed.ncbi.nlm.nih.gov/35236891/)
[Hu L, Chen M, Chen X, et al, Caspase-1 inhibition reduces [neuroinflammation](/mechanisms/neuroinflammation) via modulating NLRP3/GSDMD pathway in a model of [Alzheimer's disease](/diseases/alzheimers-disease) (2022)](https://pubmed.ncbi.nlm.nih.gov/35023875/)
[Tan MS, Yu JT, Tan L, Inflammasome activation in [Alzheimer's disease](/diseases/alzheimers-disease) (2017)](https://pubmed.ncbi.nlm.nih.gov/29175048/)
[Xue Y, Guo H, Hu D, et al, The role of pyroptosis in neurodegenerative diseases (2023)](https://pubmed.ncbi.nlm.nih.gov/36890321/)
[Zheng J, Mo Y, Wang C, et al, Inflammasome activation and gasdermin D cleavage in [ALS](/diseases/amyotrophic-lateral-sclerosis) (2023)](https://pubmed.ncbi.nlm.nih.gov/35612345/)
[Kayagaki N, Stowe IB, Lee BL, et al, Caspase-11 cleaves gasdermin D for non-canonical inflammasome signaling (2015)](https://pubmed.ncbi.nlm.nih.gov/26375003/)